» Articles » PMID: 20615971

Genetic Inhibition of PKA Phosphorylation of RyR2 Prevents Dystrophic Cardiomyopathy

Overview
Specialty Science
Date 2010 Jul 10
PMID 20615971
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant intracellular Ca(2+) regulation is believed to contribute to the development of cardiomyopathy in Duchenne muscular dystrophy. Here, we tested whether inhibition of protein kinase A (PKA) phosphorylation of ryanodine receptor type 2 (RyR2) prevents dystrophic cardiomyopathy by reducing SR Ca(2+) leak in the mdx mouse model of Duchenne muscular dystrophy. mdx mice were crossed with RyR2-S2808A mice, in which PKA phosphorylation site S2808 on RyR2 is inactivated by alanine substitution. Compared with mdx mice that developed age-dependent heart failure, mdx-S2808A mice exhibited improved fractional shortening and reduced cardiac dilation. Whereas application of isoproterenol severely depressed cardiac contractility and caused 95% mortality in mdx mice, contractility was preserved with only 19% mortality in mdx-S2808A mice. SR Ca(2+) leak was greater in ventricular myocytes from mdx than mdx-S2808A mice. Myocytes from mdx mice had a higher incidence of isoproterenol-induced diastolic Ca(2+) release events than myocytes from mdx-S2808A mice. Thus, inhibition of PKA phosphorylation of RyR2 reduced SR Ca(2+) leak and attenuated cardiomyopathy in mdx mice, suggesting that enhanced PKA phosphorylation of RyR2 at S2808 contributes to abnormal Ca(2+) homeostasis associated with dystrophic cardiomyopathy.

Citing Articles

Functional cardiac consequences of β-adrenergic stress-induced injury in a model of Duchenne muscular dystrophy.

Earl C, Javier A, Richards A, Markham L, Goergen C, Welc S Dis Model Mech. 2024; 17(10).

PMID: 39268580 PMC: 11488649. DOI: 10.1242/dmm.050852.


Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response.

Gandhi S, Sweeney H, Hart C, Han R, Perry C Cells. 2024; 13(14.

PMID: 39056750 PMC: 11274633. DOI: 10.3390/cells13141168.


Functional cardiac consequences of β-adrenergic stress-induced injury in the mouse model of Duchenne muscular dystrophy.

Earl C, Javier A, Richards A, Markham L, Goergen C, Welc S bioRxiv. 2024; .

PMID: 38659739 PMC: 11042272. DOI: 10.1101/2024.04.15.589650.


Calcium handling dysfunction and cardiac damage following acute ventricular preload challenge in the dystrophin-deficient mouse heart.

Haffner V, Nourian Z, Boerman E, Lambert M, Hanft L, Krenz M Am J Physiol Heart Circ Physiol. 2023; 325(5):H1168-H1177.

PMID: 37737731 PMC: 10907071. DOI: 10.1152/ajpheart.00265.2023.


Targeting p21-activated kinase 1 for development of a novel anti-arrhythmic drug class.

He Y, Grassam-Rowe A, Lei M, Bae J Philos Trans R Soc Lond B Biol Sci. 2023; 378(1879):20220285.

PMID: 37122206 PMC: 10150222. DOI: 10.1098/rstb.2022.0285.


References
1.
Ai X, Curran J, R Shannon T, Bers D, Pogwizd S . Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res. 2005; 97(12):1314-22. DOI: 10.1161/01.RES.0000194329.41863.89. View

2.
Townsend D, Blankinship M, Allen J, Gregorevic P, Chamberlain J, Metzger J . Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther. 2007; 15(6):1086-92. DOI: 10.1038/sj.mt.6300144. View

3.
Sood S, Chelu M, van Oort R, Skapura D, Santonastasi M, Dobrev D . Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm. 2008; 5(7):1047-54. PMC: 2525570. DOI: 10.1016/j.hrthm.2008.03.030. View

4.
Jiang M, Lokuta A, Farrell E, Wolff M, Haworth R, Valdivia H . Abnormal Ca2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res. 2002; 91(11):1015-22. DOI: 10.1161/01.res.0000043663.08689.05. View

5.
Ogata H, Ishikawa Y, Ishikawa Y, Minami R . Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009; 53(1):72-8. DOI: 10.1016/j.jjcc.2008.08.013. View